135 related articles for article (PubMed ID: 37340939)
1. Prediction of IDO1 Inhibitors by a Fingerprint-Based Stacking Ensemble Model Named IDO1Stack.
Sun H; Yang Q; Yu X; Huang M; Ding M; Li W; Tang Y; Liu G
ChemMedChem; 2023 Sep; 18(17):e202300151. PubMed ID: 37340939
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
3. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
Weng T; Qiu X; Wang J; Li Z; Bian J
Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
[TBL] [Abstract][Full Text] [Related]
4. A Risk Prediction Model for Physical Restraints Among Older Chinese Adults in Long-term Care Facilities: Machine Learning Study.
Wang J; Chen H; Wang H; Liu W; Peng D; Zhao Q; Xiao M
J Med Internet Res; 2023 Apr; 25():e43815. PubMed ID: 37023416
[TBL] [Abstract][Full Text] [Related]
5. Exploration of good and bad structural fingerprints for inhibition of indoleamine-2,3-dioxygenase enzyme in cancer immunotherapy using Monte Carlo optimization and Bayesian classification QSAR modeling.
Jain S; Bhardwaj B; Amin SA; Adhikari N; Jha T; Gayen S
J Biomol Struct Dyn; 2020 Apr; 38(6):1683-1696. PubMed ID: 31057090
[TBL] [Abstract][Full Text] [Related]
6. Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinoma.
Zhong W; Yang M; Cheng S; Hou W; Wang B; Chen J; Yu H; Ouyang Y; Wang X; Ou Z; Xu P; Li X; Zhou L; Huang J; Wang C; Lin T
Cancer Sci; 2022 Mar; 113(3):852-863. PubMed ID: 34962030
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Lee DH; Lee JY; Jeong J; Kim M; Lee KW; Jang E; Ahn S; Lee CH; Hwang JY
Molecules; 2017 Nov; 22(11):. PubMed ID: 29120388
[TBL] [Abstract][Full Text] [Related]
8. Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
Tomek P; Palmer BD; Flanagan JU; Sun C; Raven EL; Ching LM
Eur J Med Chem; 2017 Jan; 126():983-996. PubMed ID: 28011425
[TBL] [Abstract][Full Text] [Related]
9. Discovering the Active Ingredients of Medicine and Food Homologous Substances for Inhibiting the Cyclooxygenase-2 Metabolic Pathway by Machine Learning Algorithms.
Tian Y; Zhang Z; Yan A
Molecules; 2023 Sep; 28(19):. PubMed ID: 37836625
[TBL] [Abstract][Full Text] [Related]
10. Prediction of hERG potassium channel blockage using ensemble learning methods and molecular fingerprints.
Liu M; Zhang L; Li S; Yang T; Liu L; Zhao J; Liu H
Toxicol Lett; 2020 Oct; 332():88-96. PubMed ID: 32629073
[TBL] [Abstract][Full Text] [Related]
11. A new hybrid ensemble machine-learning model for severity risk assessment and post-COVID prediction system.
Shakhovska N; Yakovyna V; Chopyak V
Math Biosci Eng; 2022 Apr; 19(6):6102-6123. PubMed ID: 35603393
[TBL] [Abstract][Full Text] [Related]
12. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a stacking ensemble model for death prediction in the Chinese Longitudinal Healthy Longevity Survey (CLHLS).
Xing M; Zhao Y; Li Z; Zhang L; Yu Q; Zhou W; Huang R; Lv X; Ma Y; Li W
Maturitas; 2024 Apr; 182():107919. PubMed ID: 38290423
[TBL] [Abstract][Full Text] [Related]
14. Prediction of anti-inflammatory peptides by a sequence-based stacking ensemble model named AIPStack.
Deng H; Lou C; Wu Z; Li W; Liu G; Tang Y
iScience; 2022 Sep; 25(9):104967. PubMed ID: 36093066
[TBL] [Abstract][Full Text] [Related]
15. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.
Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K; Wu YH; Song Y; Yu B
J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
[TBL] [Abstract][Full Text] [Related]
17. Predicting the reproductive toxicity of chemicals using ensemble learning methods and molecular fingerprints.
Feng H; Zhang L; Li S; Liu L; Yang T; Yang P; Zhao J; Arkin IT; Liu H
Toxicol Lett; 2021 Apr; 340():4-14. PubMed ID: 33421549
[TBL] [Abstract][Full Text] [Related]
18. Deep Learning Algorithm Based on Molecular Fingerprint for Prediction of Drug-Induced Liver Injury.
Yang Q; Zhang S; Li Y
Toxicology; 2024 Feb; 502():153736. PubMed ID: 38307192
[TBL] [Abstract][Full Text] [Related]
19. Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Michielin O; Zoete V
J Med Chem; 2021 Dec; 64(24):17690-17705. PubMed ID: 34907770
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into the binding mechanism of IDO1 with hydroxylamidine based inhibitor INCB14943.
Wu Y; Xu T; Liu J; Ding K; Xu J
Biochem Biophys Res Commun; 2017 May; 487(2):339-343. PubMed ID: 28412361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
